Their presentation, “Investigating Imaging Modalities to Characterize Injection Deposition for Large-Volume Subcutaneous Device Design,” evaluated approaches to observing and characterizing injection deposition in ex-vivo tissue. The work is part of a broader effort to close some of the evidence gaps that still surround large-volume subcutaneous delivery.
Large-volume subcutaneous delivery is a key area of growth as drug developers look for alternatives to intravenous administration in the oncology space. Although pharmacokinetics and in-vivo testing are fundamental, the collaboration showcases what can be achieved with ex-vivo testing. The hope is that these insights will ultimately improve both device design and the patient experience.
The PDA Universe of Pre-Filled Syringes and Injection Devices Conference brings together leaders from across the pharmaceutical and medical device landscape to discuss the technologies, challenges and opportunities that are shaping the future of drug delivery.
This year’s award win highlights the value of collaboration in tackling some of the industry’s most complex challenges and reinforces Team Consulting’s position and track record developed over 40 years and over 1,000 parenteral drug delivery projects. This is Team’s third consecutive year winning the partnership award having previously won the award with AstraZeneca in 2024 and 2025.
